Pfizer (PFE) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Pfizer, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track PFE live on Mooboard →
Next 30 days1
- Oct 19, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPF-07275315 · Phase 2 · Atopic DermatitisNCT05995964: A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis. Primary completion 2026-10-19 (estimated); status RECRUITING.
31–90 days7
- Oct 30, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutEncorafenib · Phase 3 · MelanomaNCT04657991: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 29, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRimegepant · Phase 3 · Menstrual MigraineNCT06641466: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine. Primary completion 2026-11-29 (estimated); status RECRUITING.
- Dec 2, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRitlecitinib higher dose · Phase 3 · Severe Alopecia AreataNCT07029711: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata. Primary completion 2026-12-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPF-06821497 · Phase 3 · Metastatic Castration-Resistant Prostate CancerNCT06629779: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.. Primary completion 2026-12-02 (estimated); status RECRUITING.
- Dec 4, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutVLA15 · Phase 3 · Lyme DiseaseNCT07500506: A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine. Primary completion 2026-12-04 (estimated); status RECRUITING.
- Dec 8, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRitlecitinib · Phase 2 · Hidradenitis SuppurativaNCT07228390: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.. Primary completion 2026-12-08 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 11, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutdisitamab vedotin · Phase 2 · Urothelial CarcinomaNCT04879329: A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2. Primary completion 2026-12-11 (estimated); status RECRUITING.
Later17
- Dec 25, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRitlecitinib 50 mg · Phase 2 · Chronic Spontaneous UrticariaNCT07219615: A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.. Primary completion 2026-12-25 (estimated); status RECRUITING.
- Dec 28, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPF-06821497 · Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT06551324: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).. Primary completion 2026-12-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 30, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutVepdegestrant (ARV-471/PF-07850327) · Phase 3 · Breast CancerNCT05909397: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer. Primary completion 2026-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 30, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutARV-471 · Phase 1 / Phase 2 · Breast CancerNCT05573555: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B). Primary completion 2026-12-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPF-07104091 monotherapy dose escalation · Phase 2 · Small Cell Lung Cancer; Ovarian CancerNCT04553133: PF-07104091 as a Single Agent and in Combination Therapy. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutAvelumab · Phase 3 · Advanced Malignancies; NSCLCNCT05059522: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing. Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 31, 2026ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutvepdegestrant · Phase 1 / Phase 2 · Breast CancerNCT06125522: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C). Primary completion 2026-12-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 18, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRSVpreF · Phase 3 · Lower Respiratory Tract IllnessNCT05035212: Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.. Primary completion 2027-01-18 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 25, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRSVpreF · Phase 3 · Respiratory Syncytial Virus (RSV)NCT07653100: A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF. Primary completion 2027-01-25 (estimated); status RECRUITING.
- Jan 29, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutdisitamab vedotin · Phase 3 · Urothelial CarcinomaNCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2. Primary completion 2027-01-29 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 26, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPF-07220060 + PF-07104091 combination dose escalation · Phase 1 / Phase 2 · Breast Cancer; Solid TumorsNCT05262400: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors. Primary completion 2027-02-26 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 8, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPF-07275315 · Phase 2 · AsthmaNCT06977581: A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma. Primary completion 2027-03-08 (estimated); status RECRUITING.
- Mar 17, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readouttofacitinib · Phase 3 · Ulcerative ColitisNCT04624230: Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis. Primary completion 2027-03-17 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 24, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutARV-471 · Phase 1 / Phase 2 · Breast CancerNCT05548127: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A). Primary completion 2027-03-24 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 31, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutATM-AVI · Phase 2 · Gram-negative Bacterial InfectionsNCT05639647: Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections. Primary completion 2027-03-31 (estimated); status RECRUITING.
- Mar 31, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutRitlecitinib · Phase 3 · VitiligoNCT06163326: A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo. Primary completion 2027-03-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Apr 25, 2027ClinicalTrials.gov ↗Pfizer(PFE)Phase 2/3 readoutPart A: ATM-AVI Single Dose, Cohorts 1-4 · Phase 2 · Gram-negative Bacterial InfectionNCT06462235: A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH). Primary completion 2027-04-25 (estimated); status RECRUITING.
How Pfizer has moved — past-year price reactions
How binary is PFE? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
0.9%
0
23.7%
249
Largest single-day moves
- +6.8%2025-09-30no matched headline
- +6.8%2025-10-01no matched headline
- +4.6%2025-11-11no matched headline
- +3.9%2026-02-04no matched headline
- +3.6%2026-08-19no matched headline
- -3.4%2025-10-06no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
Pfizer — active clinical pipeline
Pfizer's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
91 assets137 programsPh1 37Ph2 32Ph3 61· 7 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceCardiovascularInfectiousRare / GeneticOther
PF-08634404Oncology
tucatinibOncology · HER2
Phase 2
disitamab vedotinOncology · HER2 ADC
Phase 3
EtrasimodAutoimmune · S1P
Phase 1
Phase 3
RimegepantNeuroscience · CGRP
Sigvotatug VedotinOncology · ITGB6
AbrocitinibImmunology · JAK1
Phase 3
BerobenatideMetabolic
Phase 3
ibuzatrelvirInfectious
RSVpreFInfectious
TilrekimigImmunology
Phase 3
ARV-471Oncology
Phase 3
AvelumabOncology · PD-L1
Phase 3
C.difficile vaccineOther
DazukibartAutoimmune · IFNB1
Phase 3
EnzalutamideOncology · AR
LorlatinibOncology · ALK
Multivalent Group B streptococcus vaccineInfectious
Phase 3
nirmatrelvirInfectious · Replicase polyprotein 1a
Phase 3
PF-06741086Rare / Genetic
Phase 3
PF-06821497Oncology
PF-06823859Autoimmune · IFNB1
Phase 3
PF-06838435/ fidanacogene elaparvovecRare / Genetic
Phase 3
PF-06939926Rare / Genetic
Phase 3
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene TherapyRare / Genetic
Phase 3
PG4Other
Phase 3
PG4 Multivalent VaccineOther
Phase 3
Rimegepant (PF-07899801)Neuroscience · CGRP
Phase 3
Rimegepant/BHV3000Neuroscience
Phase 3
Ritlecitinib 100 mgAutoimmune · ITK/JAK3
Phase 3
Ritlecitinib higher doseAutoimmune
Phase 3
RSVpreF VaccineInfectious
talazoparib plus enzalutamideOncology
Phase 3
Talazoparib with enzalutamideOther
Phase 3
tofacitinibAutoimmune
Phase 3
Vepdegestrant (ARV-471/PF-07850327)Oncology
Phase 3
VLA15Other
Phase 3
PalbociclibOncology · CCND1/CDK4
Phase 2
C. difficile vaccine (previously studied formulation).Other
Elranatamab (PF-06863135)Oncology · BCMA×CD3
Phase 2
Low Dose PF-07328948Cardiovascular
Phase 2
MET233 and MET097Metabolic
Part A: ATM-AVI Single Dose, Cohorts 1-4Infectious
PF-06835375Autoimmune
PF-07104091 monotherapy dose escalationOncology
Phase 2
PF-07220060 + PF-07104091 combination dose escalationOncology
Phase 2
PF-07220060 CDK4 inhibitorOncology
PF-07248144Oncology
PF-07275315Immunology
Phase 2
PF-07868489Cardiovascular
Phase 2
PF-08154225Autoimmune
Phase 2
Ritlecitinib 50 mgImmunology · ITK/JAK3
Vaccine Candidate #1Infectious
Phase 2
PF-07328948Other
AtirmociclibOther
Phase 1
E coli vaccine 1 Dose AInfectious
Phase 1
Mervometostat (PF-06821497)Oncology
PF-07799544Oncology
Phase 1
PF-07832837Immunology
Phase 1
PF-07934040Oncology
Phase 1
PF-07985631Other
Phase 1
PF-07994525Oncology
Phase 1
PF-08032562Oncology
Phase 1
PF-08046033Other
Phase 1
PF-08046050Oncology
Phase 1
PF-08046876Oncology
PF-08052667Oncology
PF-08065010Other
Phase 1
PF-08103402Immunology
Phase 1
PF-08642534Metabolic
Phase 1
PG4 vaccine in Buffer 1 with low dose PA-001Other
Phase 1
PrifetrastatOther
Phase 1
prifetrastat ReferenceOther
Phase 1
tilrekimig and rHuPH20Other
Phase 1
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
See the full biopharma catalyst calendar across all covered companies.